Advertisement

Topics

Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

07:11 EST 10 Nov 2017 | BioPortfolio Reports

Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017


Summary


According to the recently published report 'Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017'; Human Papillomavirus Protein E6 E6 pipeline Target constitutes close to 26 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes.


Human Papillomavirus Protein E6 E6 The Human Papillomavirus HPV E6 protein is one of oncoproteins encoded by the virus. It is a 151 aminoacid peptide. It plays a major role in the induction and maintenance of cellular transformation. It acts mainly as an oncoprotein by stimulating the destruction of many host cell key regulatory proteins. The complex E6/E6P targets several other substrates to degradation via the proteasome including host NFX191. The resulting increased expression of hTERT prevents the shortening of telomere length leading to cell immortalization.


The report 'Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017' outlays comprehensive information on the Human Papillomavirus Protein E6 E6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Human Papillomavirus Protein E6 E6 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 9 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Women's Health and Infectious Disease which include indications Human Papillomavirus HPV Associated Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia CIN, Head And Neck Cancer Squamous Cell Carcinoma, Head And Neck Cancer, Human Papillomavirus Infections, Lung Cancer, Metastatic Transitional Urothelial Tract Cancer and Oropharyngeal Cancer.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 E6

The report reviews Human Papillomavirus Protein E6 E6 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Human Papillomavirus Protein E6 E6 targeted therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus Protein E6 E6 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Human Papillomavirus Protein E6 E6 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 E6

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 E6 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Human Papillomavirus Protein E6 E6 Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Human Papillomavirus (HPV)
Human papilloma viruses (HPV) affect the skin and the moist membranes lining your body, for example, in your cervix, anus, mouth and throat. HPV is a common and highly contagious infection, with over three quarters of sexually active women acquiring it ...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Cervical Cancer
Cervical cancer is a malignant neoplasm of the cervix uteri or cervical area. Symptoms include vaginal bleeding, but may not present until later stages of the cancer. Cervical cancer can be treated using surgery (including local excision) in early stages...